KNSA
Kiniksa Pharmaceuticals International, plc
$61.69
-0.29 (-0.47%)
At close · Jul 15
Market Cap
$9.53B
Shares
153,876,032
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$61.69
Open$61.29
Day$60.54–62.20
52W$26.27–67.53
Avg vol 30d822K
Short int4.2M · 2.7% float · 2.9d
Short vol65%
Last earningsApr 28, 2026
DataJan 2020–Jul 2026
Filing10-Q · Apr 28
Up next
Next earnings call
Jul 28, 2026
Est · unconfirmed
· in 2 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Apr 28, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bearish
Fundamentals
Excellent
Quant / Vol
High
Market backdrop
VIX 15.7 · calm
Equity put/call 0.69
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+34%
above
Price vs 50-day avg
+10%
above
RSI (14)
56
neutral
MACD trend
Negative
52-week position
86%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+18%
trailing
6-month return
+47%
trailing
YTD return
+50%
this year
Relative strength
+37%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $56 › 200d $46 — 50d above 200d
Institutional flow
Distributing
12 of 229 funds reported for Jun 30 · net -10.0K sh shares · +5 new
Insider flow
Distributing
Net -$32.8M over 90 days · 100% sells
Short interest
Rising
2.70% of float · ▲ +41.0% MoM · 2.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
229 holders — near 2-yr high, broad support
Squeeze score
61
elevated · 0–100
Fundamentals
Revenue growth
+60%
Y/Y
EPS growth
+225%
Y/Y
Free cash flow
$136.4M
Valuation
P/E 68
rich
Balance sheet
$165.6M
net cash
Quant / Vol
risk profile
Volatility
44%
annualized · 1-yr
Max drawdown
−21%
past year
ATR
4.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Apr 28, 2026
ARCALYST net product revenue
· 2026
Raised
$930M – $945M
prior FY $677.56M
midpoint +38.4% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+34%
Bullish
Price vs 50-day avg
+10%
Bullish
RSI (14)
56
Neutral
MACD trend
Negative
Bearish
52-week position
86%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $56 › 200d $46 — 50d above 200d
Institutional flow
Distributing
12 of 229 funds reported for Jun 30 · net -10.0K sh shares · +5 new
Insider flow
Distributing
Net -$32.8M over 90 days · 100% sells
Short interest
Rising
2.70% of float · ▲ +41.0% MoM · 2.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
229 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $26
Now $62 · 86%
52-wk high $68
vs 200-day avg +34%
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| ARCALYST net product revenue | $214.3M | Q1 2026 | — |
|
|
|||
| Cash, cash equivalents, and short-term investments | $468.1M | as of March 31, 2026 | — |
| Average total duration of ARCALYST therapy in recurrent pericarditis | 3 | as of Q4 2025 | — |
| Gross-to-net | 8.4% | the full year 2025 | — |
| Multiple-recurrence patients (addressable population) | 14,000 | the fourth quarter of 2025 | — |
| Multiple-recurrence patients actively on ARCALYST treatment (as a share of the 14,000 multiple-r | 18% | the fourth quarter of 2025 | — |
| Prescribers who have written ARCALYST prescriptions for recurrent pericarditis since launch | 4,150 | since launch (as of Q4 2025) | — |
| Year-over-year ARCALYST sales growth | 62% | the full year 2025 | — |
| Multiple-recurrence patient population | 14,000 | Q4 2025 | — |
| Multiple-recurrence patients actively on ARCALYST treatment | 18% | Q4 2025 | — |
| Prescribers who have written ARCALYST prescriptions for recurrent pericarditis | 4,150 | since launch | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KNSA
this stock
Kiniksa Pharmaceuticals International, plc
|
$9.53B | +49.6% | +60.1% | 68.0 | 2.7% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$52.45B | +5.5% | — | — | 0.2% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$51.90B | — | — | — | 0.0% |
|
GALDY
Galderma Group AG/ADR
|
$48.68B | -0.2% | — | — | 0.0% |
|
HLN
Haleon plc
|
$42.98B | -3.6% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KNSA | -4.7% | +17.9% | +47.5% | -3.5% | +49.6% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | -6.0% | +18.0% | +37.4% | -4.6% | +38.9% |
Key facts
CIK
1730430
CUSIP
G52694109
13F (30d)
13 filings
12 filers
Visit website
Investor relations